SCHEMBL11946201

SCHEMBL11946201

CC1(COc2c(N3CCN(S(=O)(=O)Cc4ccc(-c5cccc(C(N)=O)c5)cc4)CC3)cnn(-c3cc(F)cc(F)c3)c2=O)CC1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 1/20 0.35
▸ MAPT P10636 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ NCOA2 Q15596 1/20 0.34
▸ NCOA1 Q15788 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ NCOA3 Q9Y6Q9 1/20 0.34
▸ SSTR2 P30874 1/20 0.34
▸ MRGPRX1 Q96LB2 1/20 0.33
▸ FAAH O00519 6/20 0.32
▸ DRD2 P14416 6/20 0.32
▸ DRD3 P35462 6/20 0.32
▸ NR3C2 P08235 1/20 0.32
▸ GCK P35557 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ GLA P06280 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11946198 0.87 CYP17A1 (0.42) MAPTPOLBCYP3A4CYP2C19PPARG
SCHEMBL11946199 0.86 CYP17A1 (0.34) MAPTPOLBCYP3A4CYP2C19PPARG
SCHEMBL11946203 0.86 MAPT (0.36) MAPTPOLBCYP3A4CYP2C19PPARG
SCHEMBL11944396 0.86 MAPT (0.38) MAPTPOLBCYP3A4CYP2C19PPARG
SCHEMBL11946195 0.86 MAPT (0.38) MAPK1MAPTPOLBCYP3A4CYP2C19
SCHEMBL11945453 0.86 MAPT (0.45) MAPK1MAPTPOLBCYP3A4CYP2C19
SCHEMBL11945631 0.86 MAPT (0.35) MAPTPOLBCYP3A4CYP2C19PPARG
SCHEMBL11945290 0.84 MAPT (0.38) MAPTPOLBCYP3A4CYP2C19PPARG
SCHEMBL11946465 0.84 MAPT (0.37) MAPK1MAPTPOLBCYP3A4CYP2C19
SCHEMBL11946202 0.84 MAPT (0.35) MAPTPOLBCYP3A4CYP2C19PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2586778-A2 Pyridazinone derivatives useful as glucan synthase inhibitors Merck Sharp & Dohme Corp. (US) 2013-05-01 — — EP disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPK1 1289/4885MAPT 2295/4885POLB 1088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback